AbbVie (ABBV) has received approval from the U.S. Food and Drug Administration (FDA) for a supplemental new drug application involving its combination regimen featuring venclexta and acalabrutinib. This combination is aimed at treating adult patients who have not previously received treatment for chronic lymphocytic leukemia. The FDA's decision was based on data gathered from the Phase 3 AMPLIFY trial, which demonstrated the effectiveness of this regimen in addressing the condition.
https://www.gurufocus.com/news/8635442/fda-approves-abbvies-abbv-new-treatment-combo-for-leukemia
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.